FMR LLC reports beneficial ownership of 2,493,136.73 shares of Apogee Therapeutics common stock, representing 4.0% of the class. The filing lists sole dispositive power of 2,493,136.73 shares and sole voting power of 2,491,555 in the cover data.
The Schedule 13G/A identifies FMR LLC as the filer and notes that one or more other persons have the right to receive dividends or sale proceeds but that no other person holds more than 5% of the class. Signatures show authorization under a power of attorney dated April 13, 2026.
Positive
None.
Negative
None.
Insights
FMR LLC holds a passive 4.0% stake in Apogee Therapeutics.
The filing reports 2,493,136.73 shares beneficially owned with sole dispositive power of the same amount and sole voting power of 2,491,555. The filing is styled as a Schedule 13G/A, indicating a passive investment reporting posture.
Dependences and risks include the noted third‑party rights to dividends or proceeds; the filing states no other person holds over 5%. Subsequent filings would show any change in stake or voting/dispositive arrangements.
Key Figures
Filing type:Schedule 13G/ABeneficially owned:2,493,136.73 sharesPercent of class:4.0%+2 more
5 metrics
Filing typeSchedule 13G/AAmendment No. 4 cover data
Sole voting power2,491,555 sharesCover page voting power line
Sole dispositive power2,493,136.73 sharesCover page dispositive power line / Item 4(iii)
Key Terms
Schedule 13G/A, beneficially owned, 13d-1(k) agreement, dispositive power
4 terms
Schedule 13G/Aregulatory
"Item 1. (a) Name of issuer: APOGEE THERAPEUTICS INC"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
13d-1(k) agreementregulatory
"Exhibit Information Please see Exhibit 99 for 13d-1(k) (1) agreement."
dispositive powerfinancial
"Item 4. (iii) Sole power to dispose or to direct the disposition of: 2493136.73"
Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.
How many Apogee Therapeutics (APGE) shares does FMR LLC report owning?
FMR LLC reports beneficial ownership of 2,493,136.73 shares. The Schedule 13G/A states this amount equals 4.0% of Apogee Therapeutics common stock as shown in the filing.
What voting and dispositive powers does FMR LLC report for APGE shares?
FMR reports sole voting power of 2,491,555 and sole dispositive power of 2,493,136.73 shares. Shared voting and dispositive powers are recorded as 0.00 in the filing cover data.
Does the filing indicate anyone else holds more than 5% of APGE?
No other person is listed as holding more than 5%. The Schedule 13G/A states one or more other persons may receive dividends or proceeds but none holds over 5% of the common stock.
Who signed the Schedule 13G/A and what authorization is referenced?
Richard Bourgelas signed on behalf of FMR LLC and Abigail P. Johnson. The signatures reference a power of attorney effective April 13, 2026, incorporated by reference to an earlier exhibit filing.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 4)
APOGEE THERAPEUTICS INC
(Name of Issuer)
COMMON STOCK
(Title of Class of Securities)
03770N101
(CUSIP Number)
06/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
03770N101
1
Names of Reporting Persons
FMR LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
2,491,555.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
2,493,136.73
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,493,136.73
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.0 %
12
Type of Reporting Person (See Instructions)
HC
SCHEDULE 13G
CUSIP Number(s):
03770N101
1
Names of Reporting Persons
Abigail P. Johnson
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
2,493,136.73
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,493,136.73
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.0 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
APOGEE THERAPEUTICS INC
(b)
Address of issuer's principal executive offices:
221 CRESCENT ST., BUILDING 17,SUITE 102B,,Waltham,MA,USA,02453
Item 2.
(a)
Name of person filing:
FMR LLC
(b)
Address or principal business office or, if none, residence:
245 Summer Street, Boston, Massachusetts 02210
(c)
Citizenship:
Not applicable
(d)
Title of class of securities:
COMMON STOCK
(e)
CUSIP No.:
03770N101
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
2493136.73
(b)
Percent of class:
4.0 %
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
Please see the responses to Items 5 and 6 on the cover page.
(ii) Shared power to vote or to direct the vote:
0.00
(iii) Sole power to dispose or to direct the disposition of:
2493136.73
(iv) Shared power to dispose or to direct the disposition of:
0.00
Item 5.
Ownership of 5 Percent or Less of a Class.
Ownership of 5 percent or less of a class
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of APOGEE THERAPEUTICS INC. No one other person's interest in the COMMON STOCK of APOGEE THERAPEUTICS INC is more than five percent of the total outstanding COMMON STOCK.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
See attached Exhibit 99.
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
FMR LLC
Signature:
Richard Bourgelas
Name/Title:
Duly authorized under Power of Attorney effective as of April 13, 2026, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
Date:
07/07/2026
Abigail P. Johnson
Signature:
Richard Bourgelas
Name/Title:
Duly authorized under Power of Attorney effective as of April 13, 2026, by and on behalf of Abigail P. Johnson*
Date:
07/07/2026
Comments accompanying signature: *This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on April 29,2026, accession number: 0000315066-26-000738.
